Introduction {#ddg13749-sec-0050}
============

Fumaric acid esters (FAEs) are widely used for systemic therapy of moderate‐to‐severe psoriasis in Germany, with a prescription rate of more than 50 %. Fumaric acid esters are also used frequently in the Netherlands, United Kingdom, and Ireland for first‐line treatment [1](#ddg13749-bib-0001){ref-type="ref"}, [2](#ddg13749-bib-0002){ref-type="ref"}. Until recently, a mixture of four different fumaric acid esters including the main active compound dimethyl fumarate (DMF, Fumaderm^®^) was only authorized in Germany. Since 2017, a product containing DMF alone (Skilarence^®^) has been authorized in Europe and is now available outside Germany as well.

The advantages of the DMF product are that the only active substance it contains is DMF, flexible dosing is possible using the 30 mg and 120 mg tablets, and the DMF product is cheaper than the FAE mixture in Germany. The only requirement for safety monitoring is ensuring that laboratory parameters are within the normal range every three months. Switching from the FAE mixture to the DMF product therefore seems reasonable.

There are no data yet as to whether a direct switch from the FAE mixture to the DMF product can be performed without a washout period. A prospective study was performed to address this issue. Patients who were stable under treatment with the FAE mixture were asked to switch to the DMF product. Patients were asked about tolerability and other treatment‐related parameters at the first follow‐up visit after switching.

Methods {#ddg13749-sec-0060}
=======

This prospective observational trial was approved by the Ethics Committee of the University of Kiel (AZ: D553/17). Patients who were treated with the FAE mixture and presented at the outpatient service of the Kiel Psoriasis Center for routine safety monitoring were asked to participate, and written informed consent was obtained before they entered the study. Patients whose psoriasis had improved and who could tolerate treatment with the FAE mixture were recruited.

Treatment with the FAE mixture was switched to the DMF product without any interruption on the basis of the current DMF dose in the FAE mixture. Patients were then scheduled for the next regular check‐up three months later.

To assess psoriasis severity, we used the PASI (psoriasis area and severity index). When presenting for their first check‐up after switching, patients were handed a questionnaire to investigate their views about tolerability and efficacy and to provide a global judgment of the switch.

Results {#ddg13749-sec-0070}
=======

A total of 40 patients (24 male, 16 female) were prospectively and consecutively recruited to the study and underwent a check‐up after switching treatments.

The age of adult patients ranged from 18 to 74 years with a mean age of 46 years. One patient was 13 years old and received treatment off‐label. Table [1](#ddg13749-tbl-0001){ref-type="table"} shows the demographics of the patients and the DMF dose at the time of switching from the FAE mixture to the DMF product. Most patients were treated with a daily DMF dose between 120 mg and 480 mg, and had previously been treated with the FAE mixture for one to five years (Figure [1](#ddg13749-fig-0001){ref-type="fig"}).

###### 

Demographic characteristics of patients before switching from the FAE mixture to the DMF product, including the daily dose of DMF at the time of switching. One patient received a dose of DMF of 120 mg every third day; the calculated daily dose was 40 mg

  Pat. No.   m/f   [\*](#ddg13749-tbl1-note-0001){ref-type="fn"}FDPso   Age   [\*\*](#ddg13749-tbl1-note-0002){ref-type="fn"}DMF   Start DMF   Duration of FAE‐mixture therapy (months)   Comorbidity                                                                                                                    Comedication                                                                                                                                                              Smoking   Alcohol   [\*\*\*](#ddg13749-tbl1-note-0003){ref-type="fn"}Previous therapies
  ---------- ----- ---------------------------------------------------- ----- ---------------------------------------------------- ----------- ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------- --------- ---------------------------------------------------------------------
  1          m     1984                                                 44    120                                                  01/2017     11                                         Rosacea                                                                                                                        None                                                                                                                                                                      Yes       Yes       CS, CS+D3
  2          m     Unknown                                              33    720                                                  02/2017     9                                          None                                                                                                                           None                                                                                                                                                                      Unknown   No        CS, (UVB)
  3          m     1984                                                 57    240                                                  2009        108                                        None                                                                                                                           None                                                                                                                                                                      Unknown   No        CS, D3
  4          m     1995                                                 67    120                                                  2009        84                                         Hypertension, muscle pain, coronary artery disease, disc prolapse                                                              Ramipril, aspirin, ­nitroglycerine, ibuprofen                                                                                                                             Yes       No        CS, CS+D3, dithranol
  5          m     2001                                                 35    240                                                  12/2015     27                                         Upper airway syndrome, sleep apnea                                                                                             None                                                                                                                                                                      No        Yes       CS, (UVB)
  6          m     1989                                                 56    600                                                  1996        84                                         None                                                                                                                           None                                                                                                                                                                      Yes       No        CS, MTX, PUVA
  7          m     1995                                                 53    480                                                  03/2012     68                                         None                                                                                                                           None                                                                                                                                                                      Yes       Yes       None
  8          f     2011                                                 61    360                                                  03/2017     8                                          None                                                                                                                           None                                                                                                                                                                      Yes       Yes       CS, CS+D3
  9          m     2013                                                 49    120                                                  01/2014     45                                         Recurrent tonsillitis, asthma                                                                                                  Pantoprazole, inhaled ­steroids                                                                                                                                           Yes       Yes       CS
  10         m     2000                                                 57    480                                                  12/2014     37                                         Hypercholesterolemia, hypertension,                                                                                            Simvastatin, diltiazem                                                                                                                                                    No        Yes       CS, D3
  11         f     1995                                                 49    480                                                  07/2015     30                                         None                                                                                                                           L‐thyroxine                                                                                                                                                               Unknown   No        CS, CS+D3, UVB
  12         f     1997                                                 52    240                                                  01/2017     11                                         None                                                                                                                           None                                                                                                                                                                      Yes       Yes       PUVA
  13         f     1988                                                 62    720                                                  07/2008     115                                        Reflux esophagitis                                                                                                             Pantoprazole                                                                                                                                                              Yes       No        Dithranol
  14         f     2009                                                 42    120                                                  07/2013     51                                         None                                                                                                                           Pantoprazole                                                                                                                                                              Yes       No        PUVA
  15         m     2007                                                 43    360                                                  06/2016     17                                         None                                                                                                                           None                                                                                                                                                                      Yes       No        CS, UVB
  16         f     1987                                                 44    60                                                   11/2015     23                                         None                                                                                                                           None                                                                                                                                                                      Unknown   No        PUVA, CS
  17         f     2010                                                 13    30                                                   07/2013     54                                         None                                                                                                                           None                                                                                                                                                                      No        No        None
  18         m     1999                                                 38    240                                                  12/2014     36                                         None                                                                                                                           None                                                                                                                                                                      Unknown   Yes       CS, D3, UVB
  19         m     1992                                                 47    240                                                  09/2014     40                                         Hypothyroidism                                                                                                                 L‐thyroxine                                                                                                                                                               Yes       Yes       D3, CS+D3
  20         m     1997                                                 74    240                                                  07/2017     7                                          Prostate cancer, COPD, hypothyroidism, ­osteoporosis, ventricular cardiac arrhythmia                                           Alendronic acid, levothyroxine, omeprazole, aspirin, flecainide, atorvastatin, sotalol, budesonide, tiotropium, ipratropium, salbutamol, n‐butylscopolamine, ­oxaceprol   Yes       Yes       UVB
  21         f     2004                                                 26    480                                                  01/2016     23                                         Hypothyroidism, hypersomnia                                                                                                    L‐thyroxine, bupropion                                                                                                                                                    No        No        PUVA
  22         m     2012                                                 63    360                                                  11/2016     13                                         Tremor                                                                                                                         Propranolol                                                                                                                                                               Yes       Yes       PUVA
  23         f     1984                                                 61    60                                                   07/2015     28                                         Lung emphysema                                                                                                                 None                                                                                                                                                                      Yes       No        CS+D3, UVB
  24         m     1996                                                 34    360                                                  01/2014     47                                         None                                                                                                                           None                                                                                                                                                                      Yes       Yes       CS, D3, CS+D3, PUVA
  25         m     2000                                                 37    240                                                  10/2014     39                                         None                                                                                                                           None                                                                                                                                                                      Unknown   Yes       None
  26         f     2002                                                 26    240                                                  10/2016     14                                         Migraine‐like headache                                                                                                         Metamizole                                                                                                                                                                Yes       No        None
  27         m     1995                                                 46    240                                                  07/2015     28                                         Dilated cardiomyopathy, complete left atrial block, single coronary occlusion, hypertension, adiposity, hyperlipoproteinemia   Aspirin, metoprolol, ­ramipril, torsemide, eplerenone, ­simvastatin                                                                                                       Yes       No        CS, CS+D3, MTX, golimumab, PUVA
  28         m     2000                                                 47    120                                                  03/2016     19                                         None                                                                                                                           None                                                                                                                                                                      Yes       Yes       CS, D3
  29         m     1970                                                 54    480                                                  03/2017     8                                          Hypertension, depressive mood disorder                                                                                         Amlodipine, St. John\'s wort                                                                                                                                              Yes       Yes       CS, UVB
  30         f     2009                                                 25    30                                                   11/2011     72                                         None                                                                                                                           None                                                                                                                                                                      Unknown   No        CS
  31         m     2011                                                 30    480                                                  03/2012     68                                         None                                                                                                                           None                                                                                                                                                                      Yes       Yes       None
  32         f     1958                                                 69    360                                                  1997        48                                         None                                                                                                                           Candesartan                                                                                                                                                               Unknown   No        CS
  33         m     1973                                                 54    240                                                  09/2011     74                                         Hypertension, ­hypercholesterolemia                                                                                            Atorvastatin, minoxidil, spironolactone, nebivolol, candesartan, doxazosin                                                                                                No        No        D3, PUVA
  34         f     1965                                                 59    720                                                  2009        60                                         Radicular pain ­syndrome                                                                                                       None                                                                                                                                                                      Yes       No        None
  35         f     2006                                                 70    360                                                  02/2017     9                                          Type 2 diabetes, ­hyperlipidemia, ­coronary artery disease, disc prolapse                                                      Insulin, aspirin, atorvastatin, diclofenac, nitroglycerine                                                                                                                No        No        CS, CS+D3
  36         f     2012                                                 27    40                                                   04/2014     42                                         None                                                                                                                           None                                                                                                                                                                      No        No        Systemic ­steroid
  37         m     2008                                                 30    Unknown                                              08/2017     3                                          Asthma, ­adiposity, alopecia areata ­universalis,                                                                              None                                                                                                                                                                      No        Yes       MTX, ­systemic ­steroid, CS
  38         m     2003                                                 39    720                                                  04/2017     6                                          Kyphosis, scoliosis                                                                                                            None                                                                                                                                                                      No        Yes       CS, D3
  39         m     2012                                                 18    720                                                  05/2017     5                                          None                                                                                                                           None                                                                                                                                                                      Unknown   No        CS
  40         f     2005                                                 24    360                                                  11/2016     12                                         Vitiligo                                                                                                                       None                                                                                                                                                                      No        No        UVB

\*FDPso: Time point of first psoriasis diagnosis.

\*\*DMF: Corresponding dose of DMF in the FAE mixture at the time of switching.

\*\*\*Previous psoriasis treatments. CS: topical steroids, CS+D3: fixed topical combination of steroid and vitamin D3 analog; D3: topical vitamin D3 analogs; MTX: ­methotrexate; UVB: broad or narrow‐band UVB; PUVA: psoralen + UVA.
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![Number of patients related to the duration of continuous FAE therapy that they received before switching from the FAE mixture to the DMF product (n = 40).](DDG-17-906-g001){#ddg13749-fig-0001}

In general, the patients regarded the outcome of the switch to the DMF product as neutral or positive (18 positive, 18 neutral, 4 negative). Efficacy as assessed with the PASI was equal or better in 34/37 patients, while 3/37 had a higher PASI severity after switching (Figure [2](#ddg13749-fig-0002){ref-type="fig"}). A PASI estimate was not available at one of the visits in 3/40 patients.

![Clinical course of PASI in patients treated with the FAE mixture before (t1) and after (t2) switching to the DMF product. The mean time between the two visits was 91.8 days (minimum 42 days, maximum 133 days; n = 37).](DDG-17-906-g002){#ddg13749-fig-0002}

According to regulatory requirements, both drug products have a similar formulation. Therefore, adverse drug effects such as gastrointestinal (GI) complaints should not differ in symptoms or intensity. The majority of patients (27/40) did not experience any difference in GI complaints after switching from the FAE mixture to the DMF product. Gastrointestinal tolerability was judged as better for the DMF product by 7/40 patients and worse by 2/40 patients. No GI complaints were reported with either drug product by 4/40 patients. Flushing was unchanged in 24/40 patients, 8/40 reported less flushing and 6/40 reported more flushing. Flushing did not occur with either drug product in 2/40 patients.

Regarding the question of overall tolerability, 28/40 patients reported similar tolerability, 8/40 reported better tolerability with the DMF product and 4/40 said that tolerability was worse after switching. In answer to the question about skin status in general, 27/40 patients reported that it was unchanged after switching from the FAE mixture to the DMF product, patients, 7/40 reported that it was better and 6/40 said it was worse.

Discussion {#ddg13749-sec-0080}
==========

Therapy of systemic psoriasis with FAE has a long tradition in Germany and also in the Netherlands. In Germany, a mixture of DMF and three salts of ethyl hydrogen fumarate (Fumaderm^®^) has been authorized since 1994; the FAE mixture has been made up in compounding pharmacies in the Netherlands. Scientific evidence has shown that DMF is the active ingredient in the FAE mixture, and acts as a prodrug for the main DMF metabolite (monomethyl fumarate; MMF) after oral administration [3](#ddg13749-bib-0003){ref-type="ref"}. In fact, the first DMF product was registered earlier for the treatment of relapsing‐remitting multiple sclerosis (Tecfidera^®^). Since fall 2017, another DMF product has been approved for oral first‐line therapy of moderate‐to‐severe plaque psoriasis (Skilarence^®^) [4](#ddg13749-bib-0004){ref-type="ref"}.

The extent of gastrointestinal symptoms and flushing depends on the formulation of the DMF‐containing drugs. Due to regulatory requirements, the FAE mixture and the DMF product have similar formulations. Consistent with this, the results of our observational study showed that the majority of our patients did not observe any difference after switching from the FAE mixture to the same dose of DMF. This was also shown for flushing, although there is little evidence that flushing depends on the details of the formulation.

Omitting the three salts of ethyl hydrogen fumarate from the FAE mixture did not result in any change in the tolerability or efficacy of the DMF product. As stated in a recent review, there is no scientific evidence that ethyl hydrogen fumarate salts have a pharmacological effect in psoriasis [5](#ddg13749-bib-0005){ref-type="ref"}.

Most of the patients in our study had already been treated with the FAE mixture for one to five years, and 22.5 % were long‐term users, having taken the drug for 5 to 10 years. The patients investigated in the study were clinical responders to FAE and were able to tolerate potential adverse effect such as GI complaints and flushing. The unexpectedly high proportion of patients who regarded the switch from the FAE mixture to the DMF product as positive may be due in part to the fact that recommended intervals between check‐ups are three months with the DMF product instead of one month with the FAE mixture.

In conclusion, the results of this study show that psoriasis patients can switch from the traditional FAE mixture to the same dose of DMF with similar clinical relief but without any washout period.
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